TherapeuticsMD, Inc.
TXMD
$1.20
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -41.08% | 21.94% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -41.08% | 21.94% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -41.08% | 21.94% | |||
| SG&A Expenses | 22.98% | -32.90% | |||
| Depreciation & Amortization | -5.00% | 4.17% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.12% | -30.37% | |||
| Operating Income | -150.96% | 63.68% | |||
| Income Before Tax | -904.82% | 114.64% | |||
| Income Tax Expenses | -3.23% | -- | |||
| Earnings from Continuing Operations | -657.89% | 120.11% | |||
| Earnings from Discontinued Operations | -112.32% | 428.57% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -359.13% | 141.38% | |||
| EBIT | -150.96% | 63.68% | |||
| EBITDA | -224.53% | 72.21% | |||
| EPS Basic | -357.99% | 141.48% | |||
| Normalized Basic EPS | 50.08% | -104.89% | |||
| EPS Diluted | -380.82% | 140.86% | |||
| Normalized Diluted EPS | 50.08% | -104.89% | |||
| Average Basic Shares Outstanding | 0.17% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.17% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||